1983
DOI: 10.1128/iai.42.1.368-373.1983
|View full text |Cite
|
Sign up to set email alerts
|

Renal deposition of alpha interferon in systemic lupus erythematosus

Abstract: Earlier studies from several laboratories showed that interferon-(x (IFN-ax) is present in the sera of a large percentage of patients with systemic lupus erythematosus (SLE). We now report the detection of IFN-ax by indirect immunofluorescence in renal sections of three patients with SLE but not in six control kidneys. The immunofluorescence reaction was mediated by three hyperimmune antisera to IFN-at raised in three different species, but not by any preimmune serum. The reaction was specifically blocked by a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
26
0

Year Published

1987
1987
2016
2016

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 31 publications
(28 citation statements)
references
References 13 publications
2
26
0
Order By: Relevance
“…In rheumatic diseases, autoantibodies against one cytokine or a small group of cytokines have been reported (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19), but their spectrum and clinical impact remain largely unknown. Autoantibodies against type I and type II interferons have been reported in the sera of up to 27% of patients with systemic lupus erythematosus (SLE) (8)(9)(10)(11). Their impact on the interferon gene expression signature and the pathogenesis of SLE is unclear, but their potential to influence interferon signaling, disease activity, and the response to biologic therapies could be great (11).…”
mentioning
confidence: 99%
“…In rheumatic diseases, autoantibodies against one cytokine or a small group of cytokines have been reported (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19), but their spectrum and clinical impact remain largely unknown. Autoantibodies against type I and type II interferons have been reported in the sera of up to 27% of patients with systemic lupus erythematosus (SLE) (8)(9)(10)(11). Their impact on the interferon gene expression signature and the pathogenesis of SLE is unclear, but their potential to influence interferon signaling, disease activity, and the response to biologic therapies could be great (11).…”
mentioning
confidence: 99%
“…I already mentioned lupus erythematosus. I n the blood of many patients the acid labile form of alfa-interferon has been described (HOOKS et al 1979, PANEM et al 1982, YTTERBERG and SCHNITZER 1982. It is the same form of I F N which was found by BOCCI et al in small amounts in the plasma of healthy volunteers (1985).…”
Section: Discussionmentioning
confidence: 90%
“…Surprisingly, we found broadly-reactive NAAbs against the IFN-as, usually at high titres, in~70% of these patients [36,43]; • Stimulation of IFN-a production by DNA:Ab complexes [35,36]; • Neutralizing anti-IFN-a autoantibodies in occasional patients [44][45][46]. C. High titre neutralizing anti-IFN autoantibodies in certain autoimmune diseases (see Table 3).…”
Section: Anti-ifn Antibodies In Thymoma Patientsmentioning
confidence: 82%
“…Type I IFNs are implicated generally in autoimmunization by assorted apparently confusing findings [35][36][37][38][39][40][41][42][43][44][45][46], and especially in SLE (Box 1; see Section VII). Indeed, several autoimmune disorders may follow prolonged anti-viral therapy with recombinant IFN-a2, (e.g.…”
Section: Involvement Of Type-i Interferonsmentioning
confidence: 99%